Results from an open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold correction found that a majority of patients were pleased with the results and that the incidence of adverse events compare favorably to the current label. Presented at the Advances in Cosmetic and Medical Dermatology's Maui Derm 2010 Meeting in Maui, Hawaii in January, the study assessed adverse events with Artefill six months after treatment in more than 1,000 patients. Patients received an initial treatment with Artefill, and up to two touch-ups after 30 and 60 days, until full correction was achieved. Importantly, 88 percent of patients reported a high satisfaction rating. Potential subjectreported AEs were followed up by phone (nondevice related) and/or office visit and possible granulomas were analyzed by biopsy. All study patients will complete a final in-office visit at 60-months.
TOP 5 ARTICLES FROM 2010
- Technology Connection: EMR Meets Modern Technology
Touch-screen technology may offer multiple benefits for adoption and effective use of EMRs.
By Michael Sherling, MD
- Recent Developments: What’s Next for the Dermatology Pharmaceutical Industry?
No doubt the dermatology pharmaceutical industry is undergoing a change. But what does it mean?
- Dermatology Q&A: New Directions in the Treatment of Hypopigmented Scars
A new study shows that off-label use of an unexpected agent yields promising results in the repigmentation of hypopigmented scars.
By Ted Pigeon, Senior Associate Editor
- Epidermal Barrier Dysfunction: Beyond Atopic Dermatitis
Specialists describe how a disrupted barrier contributes to common dermatoses and offer strategies for treatment.
By Joseph Bikowski, MD and Matthew Zirwas, MD
- Therapeutics Update